Fennec Q2 Sales Jump 33 Percent
Fennec Pharmaceuticals (NASDAQ:FENC) reported second quarter 2025 earnings on August 14, 2025, GAAP net product sales of $9.7 million, up 33% year over year compared to the same period last year and 10% sequentially, matching a quarterly revenue record with net product sales of $9.7 million. Management highlighted three consecutive quarters of net product sales growth through Q2 2025, major formulary wins, the advancing EU launch with partner Norgine, and upcoming data from the pivotal Japan study as potential inflection points for both sales and strategic value. This summary dissects key commercial gains and global expansion levers impacting the long-term outlook.
Pedmark, the only FDA-approved drug for cisplatin-induced ototoxicity (CIO), expanded its U.S. footprint as Fennec secured a large national oncology group formulary inclusion, reinforcing momentum in community oncology networks alongside NCCN guidelines and a new ENCOTA PQI designation. Management cited double-digit net new accounts sequentially, with strong retention among existing high-value accounts.
This accelerates exposure to the adult and adolescent-young-adult (AYA) population, which management estimates is ten times the size of the pediatric segment.
Source Fool.com
